Investopedia: OmniVision Feeds The Bears

Sometimes where there's smoke there's fire. Imaging chip developer OmniVision Technologies (Nasdaq:OVTI) has been an uncommonly controversial stock for most of its history, with recent worries focusing on whether the company was facing share loss to Sony (NYSE:SNE) and Toshiba at Apple (Nasdaq:AAPL). Now that the company has given very disappointing guidance for the next quarter, those worries have ratcheted up to a fever pitch. OmniVision shares are almost certain to be punished too far, but it will take a patient and aggressive investor to step up and fight the tide.

A Few Blurry Spots in First Quarter Results
Although OmniVision met expectations for the first quarter (and earnings actually beat by a bit), it wasn't a uniformly clean quarter. Revenue did jump 43% from last year's level, with sequential growth coming in at 7%. Shipments climbed about 1% sequentially, with ASPs up about 5%. Given that laptop/notebook computer shipments haven't been all that strong, it seems fair to assume that OmniVision's growth is coming from other product categories like phones, tablets and gaming devices.


To read the complete article, click below:
http://stocks.investopedia.com/stock-analysis/2011/OmniVision-Feeds-The-Bears-OVTI-SNE-AAPL-STM-DELL-HPQ0828.aspx

FinancialEdge: 5 Warnings Signs For Bad PR Stocks

Not all bad news is created equal. Patient and savvy long-term investors can leverage short-term setbacks into long-term winnings by realizing that the most likely outcome of a so-called disaster is not nearly as bad as the market assumes. However, some kinds of bad news are so toxic that prudent investors simply stay away entirely. How then should investors separate the "bad news in wolf's clothing" from the real bad news? Here are five key factors that may indicate when bad PR is too serious to ignore.

When the Company Causes Death
When a company's missteps result in actual deaths, there is a virtually inevitable spiral of events - none of which are positive. Not only will the news likely be full of warnings about the dangerous product/service, but follow-up stories detailing the aftermath and fallout will keep the mistake (and its perpetrators) in people's consciousness. Afterwards, there are expensive lawsuits and settlements, recovery and mitigation efforts, and press campaigns designed to make consumers forget about the incident.

Indevus Pharmaceuticals (known at the time as Interneuron) thought it had a blockbuster with the weight-loss drug Redux - that was until severe side-effects led to numerous product liability suits and the FDA ordered withdrawal from the market. All told, Wyeth, which licensed the drug from Indevus, paid out more than $20 billion in legal settlements to those who took Redux or Pondimin (another Wyeth weight loss drug), while revenue of the two drugs topped out at about $300 million in 1996.


http://financialedge.investopedia.com/financial-edge/0810/5-Warning-Signs-For-Bad-PR-Stocks.aspx